Press releases

Boston Scientific reinforces its commitment to global education and innovation

Acquisition expected to strengthen peripheral interventions business and accelerate growth in peripheral atherectomy and thrombectomy categories

PREDICt-RM collaborative study between Boston Scientific, American College of Cardiology and Yale University highlights improved outcomes in ICD and CRT-D patients followed with the LATITUDE™ System.

Boston Scientific Shockless Implant Evaluation (SIMPLE) study results presented at Heart Rhythm 2014, the Heart Rhythm Society's 35th annual scientific sessions.

Advanced Illumina™ 3D Programming Software provides highly significant pain relief in study patients.

Innovative technology designed to treat intrauterine fibroids and polyps.

Global medical solutions innovator seeks to pioneer new research into effective treatments for heart failure and related cardiac conditions.

Broad set of data reinforces commitment to advancing research and technology in electrophysiology.

Promising clinical data to be presented at annual conference.

Boston Scientific will participate in the healthcare conference on May 13, 2014. Learn how to watch the webcast or replay.

Advanced drug-eluting stent system recently received Japan Ministry of Health, Labor and Welfare approval.

Company exceeds earnings per share guidance on the strength of continued revenue growth.

Clinical trial is designed to establish the safety and effectiveness of both lead families.

Event will be held in San Francisco, site of the Heart Rhythm Society 35th Annual Scientific Sessions.

Newly approved devices include the DYNAGEN™ MINI and INOGEN™ MINI ICDs, as well as the DYNAGEN™ X4 and INOGEN™ X4 CRT-Ds.

Study to evaluate clinical outcomes and economic value of the Vercise™ Deep Brain Stimulation (DBS) System.

The first implant of the S-ICD System performed in Hong Kong.

Boston Scientific Corporation (NYSE: BSX) has received clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval in Europe for the Expect™ Slimline (SL) Needle, which is...

Reinforcing its position as a global leader in bringing new therapies to patients with heart and cardiovascular disease, Boston Scientific Corporation...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2014 on...

Real-world data on the Boston Scientific Corporation (NYSE:BSX) S-ICD System (Subcutaneous Implantable Defibrillator) are highlighted online this week...

MADIT-CRT long-term follow-up results presented at the American College of Cardiology and published in the New England Journal of Medicine.

Includes late breaking clinical trial assessing use of the Boston Scientific CRT-D therapy in patients with mild heart failure

Recognition is for delivering world class results and demonstrating a strong culture of operational excellence at Maple Grove, Minnesota manufacturing facility.

First implant took place in France, at the Nouvelles Cliniques Nantaises in Nantes.

Newest bare metal stent technology features advanced architecture and provides physicians with enhanced treatment option for patients

Appointment fills a vacancy that will result from the Board's decision to increase the number of directors comprising the Board from eleven to twelve.

Boston Scientific will participate in the healthcare conference on March 11 in Miami Beach. Learn how to watch the webcast or replay.

Boston Scientific will participate in the healthcare conference on March 4 in Boston. Learn how to watch the webcast or replay.

Boston Scientific will participate in both healthcare conferences on February 26 in New York City. Learn how to watch the webcast or replay.

Fully covered metal stent provides new treatment option for patients with refractory benign esophageal strictures

System provides physicians new option for treating complete blockages in the major arteries of the leg

Fourth quarter marks third consecutive quarter of improved performance.

Boston Scientific will participate in the healthcare conference on February 12 in New York. Learn how to watch the webcast or replay.

Boston Scientific will webcast its conference call with financial results and business highlights for Q4 and full year ended December 31, 2013. Learn how to tune in.

Global leader in complex cardiac interventions to play key role in driving innovative medical solutions.

Boston Scientific will participate in the healthcare conference on January 14 in San Francisco. Learn how to watch the webcast or replay.

Latest devices to treat heart failure and sudden cardiac arrest are designed to advance patient care.

Appointment will fill a vacancy that will result from the Board's decision to increase the number of directors comprising the Board from ten to eleven.

Represents important milestone toward making WATCHMAN device available to patients with atrial fibrillation.

Data presented at NANS 2013 show highly significant reduction in pain and high trial therapy success rate in the treatment of chronic pain.

Companies will collaborate to provide promotional support for stent system in U.S. hospitals

Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug...

Boston Scientific will participate in the healthcare conference on December 3 in New York. Learn how to watch the webcast or replay.

Brings more than 20 years of financial and healthcare industry experience, including extensive knowledge of the medtech industry.

Proprietary shaft design enables better control in hard-to-navigate vessels

First system to selectively stimulate targeted areas of the brain to manage symptoms of debilitating disease

Patients In Germany receive new transcatheter aortic valve implantation devices specially designed for total control and accurate deployment.

Boston Scientific will participate in the healthcare conference on November 12 in Scottsdale, AZ. Learn how to watch the webcast or replay.

Advances Boston Scientific's ability to more comprehensively serve the rapidly expanding global EP market.

New data demonstrate successful deployment in all 120 patients with no severe paravalvular regurgitation at 30 days

Boston Scientific will participate in the healthcare conference on November 12. Learn how to watch the webcast or replay.

REDUCE-HTN data presented today at TCT demonstrate excellent safety profile.

Boston Scientific Corporation (NYSE: BSX) will highlight the strength of its advanced portfolio and plans for delivering additional meaningful...

Transcatheter Aortic Valve Replacement (TAVR) device offers precise positioning and placement, offering physicians unprecedented control.

Jeffrey Capello to transition out of CFO role at year-end

"We accelerated our operational performance in the quarter while enhancing our ability to deliver meaningful innovation,” said CEO Mike Mahoney.

Revolutionary procedure clinically proven to provide long term reduction of asthma exacerbations

Award recognizes innovative S-ICD® System, the world's first and only subcutaneous implantable defibrillator.

Boston Scientific will webcast its conference call with financial results and business highlights for Q3 ending September 30, 2013. Learn how to tune in.

MAJESTIC trial to study self-expanding DES System designed to treat superficial femoral artery (SFA) lesions.

University of Pittsburgh independent study of contemporary heart failure devices highlights industry-leading Boston Scientific battery longevity.

Re-ROUTE trial data presented at VIVA 2013 late-breaking session

Agreement settles all stent-related disputes between the companies.

Reinforcing company's ongoing commitment to leadership in the global medical technology market.

REPRISE II data honored as Best Abstract 2013 at PCR London valves course

Represents significant milestone toward obtaining additional key regulatory approvals for the SYNERGY™ Stent System.

Unlike medications alone, bronchial thermoplasty provides benefits that last for years rather than hours

Boston Scientific will participate in the healthcare conference on September 11 in Boston. Learn how to watch the webcast or replay.

Boston Scientific will participate in the healthcare conference on September 9 in New York. Learn how to watch the webcast or replay.

First implantations in Zhejiang province and Beijing mark the launch of the COGNIS CRT-D in the Chinese market.

Products join the company's growing portfolio of next generation EP tools designed to redefine ablation technology.

Innovative bare metal stent designed to treat Peripheral Artery Disease.

Public offering consists of $600 million of 2.650% notes due October 1, 2018 and $450 million of 4.125% notes due October 1, 2023.

Company expects to receive the net offering proceeds upon closing on August 13, 2013, subject to customary closing conditions.

"As we continue to expand our portfolio, our team is inspired to deliver meaningful innovation to more patients globally," said president and CEO Mike Mahoney.

System is next-generation 3D mapping and navigation solution for use in cardiac catheter ablations and other electrophysiology (EP) procedures.

Next generation intravascular ultrasound catheter improves image quality and deliverability

First patient treated in OPTIMISE clinical trial evaluating safety, efficacy of occipital nerve stimulation using Precision™ system.

Device facilitates delivery of interventional devices in complex PCI procedures.

Boston Scientific will webcast its conference call with financial results and business highlights for Q2 ended June 30, 2013. Learn how to tune in.

Transaction to accelerate Boston Scientific expansion in growing electrophysiology market

Cardiac pacing device also features technology to help identify patients with severe sleep apnea.

New family of pacemakers monitor respiration, adjust pacing accordingly, and support insight into the patient’s overall heart failure status.

Outcomes follow recent NICE guidance supporting safety and effectiveness of subcutaneous implantable defibrillators.

VANTAGE study interim data presented at International Congress of Parkinson's Disease and Movement Disorders in Sydney.

Boston Scientific Corporation (NYSE: BSX) announces the first implantation of its Vercise™ DBS System as part of the INTREPID clinical trial. ...

Company continues to demonstrate its commitment to women's health with a research and education grant of more than $1 million for the SUPeR clinical trial.

GUIDE DBS is the world's first Deep Brain Stimulation visual simulation system.

Boston Scientific will participate in the healthcare conference on May 30 in Boston. Learn how to watch the webcast or replay.

Interim data from REDUCE-HTN clinical program presented today at EuroPCR

New data presented in late-breaking clinical trial session at EuroPCR demonstrated successful deployment of the Lotus™ Valve in the first 60 patients with minimal paravalvular regurgitation at 30 days.

Positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for coronary heart disease.

Bronchial Thermoplasty shown to provide long term asthma control over a five-year period after treatment.

More than 24 clinical presentations will feature new data and analyses on Boston Scientific endoscopy products.

Company to present a diversified set of data at the annual EuroPCR Scientific Program May 21-24 in Paris.

Study evaluates clinical outcomes of self-expanding metal stents as a bridge to surgery.

Industry-leading battery life reduces the frequency of replacement surgery.

Company offers mapping system with IntellaMap Orion™ mapping catheter in effort to significantly enhance physician treatment options.

Clinical trial data demonstrated significant reductions in both cardiovascular and all death compared to warfarin.